论文部分内容阅读
目的:评价和比较雷贝拉唑与奥美拉唑分别用于治疗幽门螺杆菌(HP)相关性胃溃疡患者的临床疗效。方法:选取2014年2月—2015年1月间收治的HP相关性胃溃疡患者72例,将其分为奥美拉唑组(36例)和雷贝拉唑组(36例);奥美拉唑患者给予奥美拉唑治疗,雷贝拉唑患者给予雷贝拉唑治疗,比较两组患者治疗后的临床总有效率和HP根除率及不良反应的发生情况。结果:雷贝拉唑组患者治疗后的总有效率和HP根除率分别为94.44%和91.67%,高于奥美拉唑组为75.00%与69.44%(P<0.05);两组患者用药后不良反应的发生率经比较其差异无统计学意义(P>0.05)。结论:雷贝拉唑用于治疗HP相关性胃溃疡患者的临床疗效优于奥美拉唑。
Objective: To evaluate and compare the clinical efficacy of rabeprazole and omeprazole in the treatment of patients with gastric ulcer associated with Helicobacter pylori (HP). Methods: Seventy-two patients with HP-associated gastric ulcer who were admitted between February 2014 and January 2015 were divided into the omeprazole group (n = 36) and the rabeprazole group (n = 36) The rabeprazole was given omeprazole, the rabeprazole was given rabeprazole, and the total clinical effective rate, HP eradication rate and adverse reactions of the two groups were compared. Results: The total effective rate and HP eradication rate after treatment in the rabeprazole group were 94.44% and 91.67%, respectively, which were higher than those in the omeprazole group (75.00% vs 69.44%, P <0.05) There was no significant difference in the incidence of adverse reactions (P> 0.05). Conclusion: Rabeprazole is superior to omeprazole in the treatment of patients with HP-associated gastric ulcer.